Metrics to compare | AVCT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVCTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.7x | −4.0x | −0.4x | |
PEG Ratio | −0.24 | −0.09 | 0.00 | |
Price/Book | 127.7x | 2.1x | 2.6x | |
Price / LTM Sales | 2,798.0x | 12.0x | 3.0x | |
Upside (Analyst Target) | 20.0% | 176.2% | 53.2% | |
Fair Value Upside | Unlock | −0.5% | 9.0% | Unlock |
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company’s lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.